Enzo Ierardi, Floriana Giorgio, Giuseppe Losurdo, Alfredo Di Leo, Mariabeatrice Principi, Division of Gastroenterology, Department of Emergency and Organ Transplantation, 70124 Bari, Italy.
World J Gastroenterol. 2013 Dec 7;19(45):8168-80. doi: 10.3748/wjg.v19.i45.8168.
Therapeutic management of Helicobacter pylori (H. pylori) remains an unsolved issue. Indeed, no therapeutic regimen is able to cure the infection in all treated patients, and in many the infection persists despite the administration of several consecutive standard therapies. Although antibiotic resistance reports describe alarming results, the outcome of therapeutic regimens does not seem to parallel this scenario in most cases, since a successful performance is often reached in more than 80% of cases. However, the phenomenon of increasing antibiotic resistance is being closely studied, and the results show controversial aspects even in the same geographic area. For the continents of Europe, America, Asia, Africa, and Oceania, minimal and maximal values of resistance to the main antibiotics (clarithromycin, amoxicillin, metronidazole, and levofloxacin) feature wide ranges in different countries. The real enigma is therefore linked to the several different therapeutic regimens, which show results that often do not parallel the in vitro findings even in the same areas. A first aspect to be emphasized is that some regimens are limited by their use in very small geographic districts. Moreover, not all therapeutic trials have considered bacterial and host factors affecting the therapeutic outcome. The additional use of probiotics may help to reduce adverse events, but their therapeutic impact is doubtful. In conclusion, the "ideal therapy", paradoxically, appears to be a "utopia", despite the unprecedented volume of studies in the field and the real breakthrough in medical practice made by the discovery and treatment of H. pylori. The ample discrepancies observed in the different areas do not encourage the development of therapeutic guidelines that could be valid worldwide. On these bases, one of the main challenges for the future might be identifying a successful solution to overcome antibiotic resistances. In this context, geography must be considered a relevant matter.
幽门螺杆菌(H. pylori)的治疗管理仍然是一个未解决的问题。事实上,没有任何治疗方案能够治愈所有接受治疗的患者的感染,而且在许多情况下,尽管给予了几次连续的标准治疗,感染仍持续存在。尽管抗生素耐药性报告描述了令人震惊的结果,但治疗方案的结果似乎在大多数情况下并不与这种情况相符,因为在 80%以上的病例中通常都能取得成功的结果。然而,抗生素耐药性增加的现象正在被密切研究,结果显示即使在同一地理区域也存在有争议的方面。对于欧洲、美洲、亚洲、非洲和大洋洲的各大洲,主要抗生素(克拉霉素、阿莫西林、甲硝唑和左氧氟沙星)的最小和最大耐药性值在不同国家的范围内差异很大。因此,真正的谜团与几种不同的治疗方案有关,这些方案的结果在同一地区往往与体外发现不相符。需要强调的一个方面是,一些方案受到其在非常小的地理区域使用的限制。此外,并非所有的治疗试验都考虑了影响治疗结果的细菌和宿主因素。益生菌的额外使用可能有助于减少不良反应,但它们的治疗效果值得怀疑。总之,尽管在该领域进行了前所未有的研究,并且通过发现和治疗 H. pylori 在医学实践中取得了真正的突破,这种“理想的治疗”似乎仍然是一种“乌托邦”。在不同地区观察到的广泛差异并不鼓励制定在全球范围内有效的治疗指南。在此基础上,未来的主要挑战之一可能是确定一种成功的解决方案来克服抗生素耐药性。在这种情况下,地理因素必须被视为一个相关的问题。